# Biotech Daily Digest — 2025-10-20

**25 items from 3 sources**

## Summary by Source

- Endpoints News: 10 items
- Fierce Biotech: 4 items
- arXiv q-bio: 11 items


## Endpoints News

- **[#ESMO25: Novartis seeks to move Pluvicto to earlier prostate cancer, but data underwhelm](https://endpoints.news/esmo25-novartis-seeks-to-move-pluvicto-to-earlier-prostate-cancer-but-data-underwhelm/)**  
  _Mon, 20 Oct 2025 14:37:56 +0000_  
  BERLIN — Novartis’ Pluvicto cut the risk of prostate cancer progression or death by 28% when added to hormone therapy, and the radiopharmaceutical also slowed progression to end-stage disease, according to the latest Phase 3 trial ...

- **[#ESMO25: Iambic Therapeutics gives first clinical readout for AI-designed cancer drug](https://endpoints.news/iambic-therapeutics-gives-first-clinical-readout-for-ai-designed-cancer-drug/)**  
  _Mon, 20 Oct 2025 11:00:14 +0000_  
  After the stumbles and underwhelming results of drugs created by the first generation of AI biotechs, results released Monday by one of the highest-profile members of the next generation look more encouraging ...

- **[Interview with Anthropic's life sciences head on AI in bio product](https://endpoints.news/interview-with-anthropics-life-sciences-head-on-ai-in-bio-product/)**  
  _Mon, 20 Oct 2025 10:00:16 +0000_  
  The AI lab Anthropic announced its first dedicated product for life sciences on Monday, after hiring a team to push the tech giant deeper into biology and the drug industry.

 Eric Kauderer-Abrams, a Stanford PhD ...

- **[#ESMO25: Ideaya’s drug saves almost 60% of eye cancer patients from surgery in Phase 2 trial](https://endpoints.news/esmo25-ideayas-drug-saves-almost-60-of-eye-cancer-patients-from-surgery-in-phase-2-trial/)**  
  _Mon, 20 Oct 2025 09:48:53 +0000_  
  BERLIN – Ideaya Biosciences said its protein kinase C inhibitor delivered positive mid-stage results in a subset of eye cancer patients, bolstering expectations for one of the cohorts in an ongoing registrational study.

 After treatment ...

- **[Eli Lilly backs anti-aging biotech NewLimit in $45M raise](https://endpoints.news/eli-lilly-backs-anti-aging-biotech-newlimit-in-45m-raise/)**  
  _Mon, 20 Oct 2025 09:00:12 +0000_  
  An anti-aging startup co-founded by a cryptocurrency billionaire appears set to become biotech’s latest unicorn.

 NewLimit said Monday that it raised $45 million from new investors like Eli Lilly’s VC arm Lilly Ventures and S32 ...

- **[#ESMO25: Exelixis says TKI extended survival in Phase 3 colorectal cancer trial](https://endpoints.news/esmo25-exelixis-says-tki-extended-survival-in-phase-3-colorectal-cancer-trial/)**  
  _Mon, 20 Oct 2025 06:30:48 +0000_  
  BERLIN — Exelixis said that a combination of its oral TKI zanzalintinib and Roche’s Tecentriq reduced the risk of death for certain patients with metastatic colorectal cancer by 20% compared to a standard of care ...

- **[#ESMO25: Sanofi, Orano Med’s radiopharmaceutical looks competitive in rare cancer](https://endpoints.news/esmo25-sanofi-orano-meds-radiopharmaceutical-looks-competitive-in-rare-cancer/)**  
  _Mon, 20 Oct 2025 06:30:11 +0000_  
  AlphaMedix, the radiopharmaceutical being developed by Sanofi and its partner Orano Med, caused tumors to shrink or disappear in 57% of patients with a rare cancer who had not received a radioligand before, according to ...

- **[FDA approves Roche's CD20 antibody Gazyva for lupus nephritis](https://endpoints.news/fda-approves-roches-cd20-antibody-gazyva-for-lupus-with-kidney-injury/)**  
  _Mon, 20 Oct 2025 05:00:46 +0000_  
  

- **[#ESMO25: Amgen, Zai Lab detail reduced survival benefit in stomach cancer trial](https://endpoints.news/esmo25-amgen-zai-lab-detail-reduced-survival-benefit-in-stomach-cancer-trial/)**  
  _Sun, 19 Oct 2025 22:05:02 +0000_  
  BERLIN — Amgen and Zai Lab shared more details about how the survival benefit of their stomach cancer drug waned in a Phase 3 trial.

 At a primary analysis for the trial ...

- **[#ESMO25: Roche claims its SERD is ‘most potent’ after data in breast cancer all-comers](https://endpoints.news/esmo25-roches-serd-is-the-first-shown-to-work-in-non-mutant-breast-cancer-patients/)**  
  _Sat, 18 Oct 2025 05:00:27 +0000_  
  Roche’s breast cancer pill giredestrant could become the first member of its class — the selective estrogen receptor degraders, or SERDs — to be approved in patients who do not have a mutated version of the receptor ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/roche-claws-its-way-toward-fda-phase-3-eye-disease-trials-yield-mixed-results" hreflang="en">Roche claws its way toward FDA as phase 3 eye disease trials yield mixed results</a>](https://www.fiercebiotech.com/biotech/roche-claws-its-way-toward-fda-phase-3-eye-disease-trials-yield-mixed-results)**  
  _Oct 20, 2025 9:03am_  
  Roche is forging ahead with plans to seek approval for an eye disease drug candidate despite missing the primary endpoint in one of its phase 3 trials.

- **[<a href="https://www.fiercebiotech.com/medtech/pair-european-biotechs-link-tackle-neurodegenerative-diseases" hreflang="en">European biotechs link to tackle neurodegenerative diseases</a>](https://www.fiercebiotech.com/medtech/pair-european-biotechs-link-tackle-neurodegenerative-diseases)**  
  _Oct 20, 2025 8:01am_  
  Two European-based biotechs—Indivi of Switzerland and Clouds of Care of Belgium—inked a collaboration deal with the goal of leveraging precision medicine tools to boost the early phase of treatments targeting neurodegenerative diseases like Alzheimer’s and Parkinson’s.

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-gsk-says-stay-tuned-more-adc-data-after-partner-hansoh-posts-49-orr" hreflang="en">ESMO: GSK says 'stay tuned' for more ADC data after partner Hansoh posts 49% response rate</a>](https://www.fiercebiotech.com/biotech/esmo-gsk-says-stay-tuned-more-adc-data-after-partner-hansoh-posts-49-orr)**  
  _Oct 18, 2025 6:39am_  
  GSK may be happy with the latest readouts from two Hansoh-partnered ADCs, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data.

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-vivace-tunes-ph-3-after-midstage-mesothelioma-trial-hits-high-note" hreflang="en">ESMO: Vivace tunes up for phase 3 after midstage mesothelioma trial hits high note</a>](https://www.fiercebiotech.com/biotech/esmo-vivace-tunes-ph-3-after-midstage-mesothelioma-trial-hits-high-note)**  
  _Oct 17, 2025 5:10pm_  
  Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant mesothelioma.


## arXiv q-bio

- **[The mechanics of $\textit{Less In More Out}$: modeling fabric-based soft robotic hearts](https://arxiv.org/abs/2510.14984)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.14984v1 Announce Type: new 
Abstract: Fabric-based soft robots combine high load-carrying capacity, efficiency, and low weight with the ability to bend, twist, contract, or extend with ease, making them promising candidates for biomedical applications such as soft total artificial hearts. While recent exper…

- **[Fertilizers Fuel, Insecticides Stabilize: Resolving the Paradox of Enrichment in Agriculture](https://arxiv.org/abs/2510.15811)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.15811v1 Announce Type: new 
Abstract: The Paradox of Enrichment (PoE) predicts that increasing resources, such as nutrient inputs like fertilizers or food availability, should destabilize ecological systems, such as crop-pest dynamics, leading to population cycles that can increase the risk of crop failure…

- **[Quantifying the Risk of Long Term Chikungunya Persistence in Miami Dade County](https://arxiv.org/abs/2510.15826)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.15826v1 Announce Type: new 
Abstract: Chikungunya virus is a mosquito-borne arbovirus with the potential to establish sustained transmission in subtropical regions like Florida, where climatic and ecological conditions support vector proliferation. In this study, we develop a Continuous Time Markov Chain mo…

- **[GENESIS: A Generative Model of Episodic-Semantic Interaction](https://arxiv.org/abs/2510.15828)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.15828v1 Announce Type: new 
Abstract: A central challenge in cognitive neuroscience is to explain how semantic and episodic memory, two major forms of declarative memory, typically associated with cortical and hippocampal processing, interact to support learning, recall, and imagination. Despite significant…

- **[Navigating the consequences of mechanical ventilation in clinical intensive care settings through an evolutionary game-theoretic framework](https://arxiv.org/abs/2510.15127)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.15127v1 Announce Type: cross 
Abstract: Identifying the effects of mechanical ventilation strategies and protocols in critical care requires analyzing data from heterogeneous patient-ventilator systems within the context of the clinical decision-making environment. This research develops a framework to help…

- **[Sparing of DNA irradiated with Ultra-High Dose-Rates under Physiological Oxygen and Salt conditions](https://arxiv.org/abs/2510.15478)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.15478v1 Announce Type: cross 
Abstract: Cancer treatment with radiotherapy aims to kill tumor cells and spare healthy tissue.Thus,the experimentally observed sparing of healthy tissue by the FLASH effect during irradiations with ultra-high dose rates (UHDR) enables clinicians to extend the therapeutic windo…

- **[SpikeFit: Towards Optimal Deployment of Spiking Networks on Neuromorphic Hardware](https://arxiv.org/abs/2510.15542)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2510.15542v1 Announce Type: cross 
Abstract: This paper introduces SpikeFit, a novel training method for Spiking Neural Networks (SNNs) that enables efficient inference on neuromorphic hardware, considering all its stringent requirements: the number of neurons and synapses that can fit on a single device, and lo…

- **[Emergence of Functionally Differentiated Structures via Mutual Information Minimization in Recurrent Neural Networks](https://arxiv.org/abs/2507.12858)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2507.12858v2 Announce Type: replace 
Abstract: Functional differentiation in the brain emerges as distinct regions specialize and is key to understanding brain function as a complex system. Previous research has modeled this process using artificial neural networks with specific constraints. Here, we propose a n…

- **[Transformer-Based Hematological Malignancy Prediction from Peripheral Blood Smears in a Real-Word Cohort](https://arxiv.org/abs/2509.20402)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2509.20402v2 Announce Type: replace 
Abstract: Peripheral blood smears remain a cornerstone in the diagnosis of hematological neoplasms, offering rapid and valuable insights that inform subsequent diagnostic steps. However, since neoplastic transformations typically arise in the bone marrow, they may not manifes…

- **[Cross-Population Amplitude Coupling in High-Dimensional Oscillatory Neural Time Series](https://arxiv.org/abs/2105.03508)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2105.03508v3 Announce Type: replace-cross 
Abstract: Neural oscillations have long been considered important markers of interaction across brain regions, yet identifying coordinated oscillatory activity from high-dimensional multiple-electrode recordings remains challenging. We sought to quantify time-varying co…

- **[Random Measures, ANOVA Models and Quantifying Uncertainty in Randomized Controlled Trials](https://arxiv.org/abs/2312.10541)**  
  _Mon, 20 Oct 2025 00:00:00 -0400_  
  arXiv:2312.10541v2 Announce Type: replace-cross 
Abstract: The paper introduces a novel approach to global sensitivity analysis, grounded in the variance-covariance structure of random variables derived from random measures. The proposed methodology facilitates the application of information-theoretic rules for uncert…
